NCT00334659已完成1 期
A Double-blind, Placebo-controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
Avexa2 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2006年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 37
- 试验地点
- 2
- 主要终点
- QTc at individual Day 7 post-dose Tmax as determined by concurrent pharmacokinetic (PK) analysis for apricitabine
研究概览
简要总结
The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects 18 - 65 years of age, inclusive.
- •Body mass index (BMI) between 18-30 kg/m2, inclusive, and a total body weight > 50 kg.
- •No clinically significant medical history.
- •No clinically significant findings on complete physical examination, including blood pressure, pulse rate and 12-lead ECG.
- •Normal clinical safety laboratory results at screening.
- •Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.
- •Willing and able to stay in the clinic for the in-patient activities required by the protocol.
排除标准
- •Evidence of clinically relevant pathology that could interfere with the study results or put the subject's safety at risk.
- •Current or recurrent disease that may affect the action, absorption or disposition of the study treatment, or clinical or laboratory assessments.
- •Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, any medical disorder requiring treatment or that may make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study treatment or procedures.
- •History of febrile illness within the 5 days prior to the first dose.
- •Positive Hepatitis B surface antigen, Hepatitis C antibody or HIV test result at screening visit.
- •Use of any prescription medication within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication or during the study. As an exception, acetaminophen may be used at doses of ≤ 1 g/day.
- •Use of any over-the-counter (OTC) medication within 7 days or 5 half-lives (whichever is longer) prior to or during the study. Herbal supplements (including herbal weight-loss or "metabolism booster" therapies) must be discontinued 28 days prior to the first dose of trial medication.
- •Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds or any of their stated ingredients.
- •Subjects with a history of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces [150 ml] of wine, 12 ounces [360 ml] of beer or 1.5 ounces [45 ml] of hard liquor) or illicit substance abuse within 6 months of screening.
- •Positive screen for alcohol or drugs of abuse during screening visit or at study check-in.
- •History or evidence of routine use of tobacco or nicotine-containing products in excess of 5 cigarettes per day (or equivalent).
- •Participated in a clinical study involving an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
- •Blood donation of one pint or more within 56 days of the start of the study.
- •Plasmapheresis or plasma donation within 30 days of the start of the study.
- •Single 12-lead ECG demonstrating QTc > 450 msec at screen. A single repeat ECG may be done at the investigator's discretion.
- •Any condition that in the opinion of the investigator would complicate or compromise the study, or the well-being of the subject.
结局指标
主要结局
QTc at individual Day 7 post-dose Tmax as determined by concurrent pharmacokinetic (PK) analysis for apricitabine
时间窗: day 7
The maximum Day 7 QTc increase from baseline observed between 1 to 4 hours post-dose, using time-matched ECG assessments
时间窗: day 7
The average Day 7 QTc observed between 1 to 4 hours post-dose
时间窗: day 7
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female SubjectsHealthyNCT02050802Actelion64
已完成
不适用
A Double-Blind, Placebo-Controlled Study for Effects of Daily Ingestion of Azuki (Vigna angularis) bean Polyphenol on Lipid Metabolism ImprovementHealthy adultsJPRN-UMIN000021975Hokkaido Information University40
已完成
不适用
A Double-Blind, Placebo-Controlled Study for Effects of Daily Oral Administration of "Dattan Soba Seikatsu" on Blood pressure and Blood flow improvement.Healthy adultsJPRN-UMIN000026254Hokkaido Information University46
进行中（未招募）
不适用
Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women”Estudio doble ciego controlado con placebo de la eficacia, seguridad y tolerancia del raloxifeno como tratamiento coadyuvante de los síntomas negativos de la esquizofrenia en mujeres postmenopáusicas.Trastorno esquizofrénicoEUCTR2004-004281-32-ESSan Joan de Déu. Serveis de Salut Mental
招募中
3 期
Ginger caplets in Post operative nausea and vomitingCTRI/2012/10/003063The Himalaya Drug Company50